As pres­sure mounts to take ac­tion on drug short­ages, law­mak­ers seek to boost pro­duc­tion in the US

Last year
Pharma
FDA+

As Ab­b­Vie cel­e­brates bet­ter-than-ex­pect­ed earn­ings, CEO Rick Gon­za­lez force­ful­ly de­fends pipeline

Last year
Pharma

In two late-stage tri­als of Lil­ly’s tirzepatide, par­tic­i­pants lost one-quar­ter of their weight

Last year
R&D

Bio­haven’s tro­r­ilu­zole re­ject­ed be­fore FDA re­view

Last year
FDA+

Uro­Gen nabs $120M to sup­port po­ten­tial 2024 NDA fil­ing, launch of blad­der can­cer chemo gel

Last year
Financing

'An un­holy union': Stan­ford sci­en­tists cre­ate a drug that flips can­cer dri­ver in­to killer

Last year
R&D

As SQZ faced a fi­nal reck­on­ing, a fate­ful board de­ci­sion steered the com­pa­ny to a quick and bru­tal endgame

Last year
Bioregnum

Mer­sana halves work­force in light of ovar­i­an can­cer tri­al flop, spelling end to its lead ADC

Last year
People
R&D

Ipsen ends neu­ro­tox­in pact with Gal­der­ma af­ter ar­bi­tra­tion cas­es filed in in­ter­na­tion­al court

Last year
Deals
Law

Pfiz­er brings on­col­o­gy R&D leader in­to C-suite, parts ways with de­vel­op­ment chief William Pao af­ter just 16 months

Last year
People
Pharma

Af­ter years of de­lay, Roche takes one of Spark’s he­mo­phil­ia gene ther­a­pies in­to PhI­II, drops an­oth­er

Last year
R&D
Cell/Gene Tx

‘This is not a sci­ence prob­lem any­more': Paths emerge for scal­ing up rare dis­ease med­i­cine

Last year
R&D
In Focus

The vet­er­an crew at Medicxi is back with a new $400M fund and an up­beat as­sess­ment of what's com­ing

Last year
Financing
Startups

Ot­su­ka, Lund­beck­'s new cam­paign spot­lights ag­i­ta­tion symp­toms in Alzheimer’s dis­ease

Last year
Pharma
Marketing

GSK bull­ish on RSV vac­cine bat­tle against Pfiz­er, ships first Arexvy dose

Last year
Pharma
Marketing

Mer­ck­'s $1.4B cy­ber­at­tack suit goes to New Jer­sey Supreme Court

Last year
Pharma
Law

Ab­b­Vie's pso­ri­a­sis drug Skyrizi beats out Am­gen's block­buster in PhIV head-to-head study

Last year
Pharma

An­oth­er dosage of Eli Lil­ly’s Moun­jaro is in short­age

Last year
Pharma
Manufacturing

House, Sen­ate com­mit­tees mark up PBM bills as mo­men­tum for re­form mounts

Last year
Pharma
FDA+

Phar­ma ad spend­ing jumps 12% in first half of 2023, ad track­er says

Last year
Pharma
Marketing

Oc­taphar­ma wins FDA ap­proval for drug to ur­gent­ly re­verse ef­fects of blood thin­ners

Last year
Pharma
FDA+

Ther­mo Fish­er's rev­enue falls in Q2 amid 'chal­leng­ing' cli­mate for biotechs and in Chi­na

Last year
Pharma
Manufacturing

Sam­sung Bi­o­log­ics touts Q2 per­for­mance af­ter ex­pand­ing deals with big phar­mas

Last year
Manufacturing

Finnish man­u­fac­tur­er to in­vest $55M+ in new fa­cil­i­ty for AAV ther­a­pies

Last year
Pharma
Cell/Gene Tx
First page Previous page 305306307308309310311 Next page Last page
A service from the Financial Times